GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (ASX:MYX) » Definitions » Interest Expense

Mayne Pharma Group (ASX:MYX) Interest Expense : A$-34.5 Mil (TTM As of Jun. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Mayne Pharma Group Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Mayne Pharma Group's interest expense for the six months ended in Jun. 2024 was A$ -13.6 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was A$-34.5 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Mayne Pharma Group's Operating Income for the six months ended in Jun. 2024 was A$ -106.2 Mil. Mayne Pharma Group's Interest Expense for the six months ended in Jun. 2024 was A$ -13.6 Mil. Mayne Pharma Group did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Mayne Pharma Group Interest Expense Historical Data

The historical data trend for Mayne Pharma Group's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mayne Pharma Group Interest Expense Chart

Mayne Pharma Group Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -31.06 -32.35 -32.10 -28.39 -34.50

Mayne Pharma Group Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.19 -26.41 -1.98 -20.86 -13.64

Mayne Pharma Group Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-34.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mayne Pharma Group  (ASX:MYX) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Mayne Pharma Group's Interest Expense for the six months ended in Jun. 2024 was A$-13.6 Mil. Its Operating Income for the six months ended in Jun. 2024 was A$-106.2 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2024 was A$35.0 Mil.

Mayne Pharma Group's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

Mayne Pharma Group did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Mayne Pharma Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mayne Pharma Group Ltd (ASX:MYX) » Definitions » Interest Expense
Comparable Companies
ASX:FRE LLY OCSE:NOVO B JNJ ABBV MRK XSWX:ROG LSE:AZN XSWX:NOVN AMGN PFE XPAR:SAN GILD BMY LSE:GSK TSE:4519 TSE:4568 SHSE:600276 TSE:4578 XTER:BAYN
Traded in Other Exchanges
MAYNF:USA HG6:Germany HG6:Germany
Address
1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Website
http://www.maynepharma.com
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.